Somatropin biosimilar - Biopartners/LG Chem

Drug Profile

Somatropin biosimilar - Biopartners/LG Chem

Alternative Names: Declage; Eutrophine; Eutropin; Eutropin Plus; LB-03002; rhGH; Somatropin Biopartners; Somatropina Biopartners; SR-rhGH; Valtropin

Latest Information Update: 17 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator LG Life Sciences
  • Developer Biopartners GmbH; LG Chem; LG Life Sciences; Merck KGaA
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Short stature; Somatotropin deficiency
  • Phase III Prader-Willi syndrome

Most Recent Events

  • 03 Aug 2017 Phase-II development for Short stature (In children, Treatment-naive) is ongoing in South Korea (SC, Controlled release)
  • 03 Aug 2017 Somatropin biosimilar is still in phase III trials for Prader-Willi syndrome (In children, In infants) in South Korea (SC, injection) (NCT02204163)
  • 02 Aug 2017 No recent reports on development identified - Registered for Somatotropin deficiency (In children, In adults) in Norway, Iceland and Liechtenstein (SC, controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top